Claims for Patent: 5,713,845

Summary for Patent: 5,713,845

Title:	Laser assisted drug delivery
Abstract:	The present invention provides a process for laser assisted drug delivery through the skin. A drug and a explosive absorber of light energy are applied topically to the skin. The treated area of the skin is illuminated with very short pulses of light which is preferentially absorbed by the absorber causing a very large number of tiny explosions. The tiny explosion forces portions of the drug to penetrate into the skin. A preferred embodiment utilizes small graphite particles and an Nd:YAG short pulse laser.
Inventor(s):	Tankovich; Nikolai (San Diego, CA)
Assignee:	ThermoLase Corporation (San Diego, CA)
Application Number:	08/489,352
Patent Claims:	1. A process for transdermal drug delivery comprising the steps of: (a) topically applying to a section of skin a drug and an explosive absorber, said absorber having a high absorption at at least one frequency band of light, (b) illuminating said section of skin with pulses of said at least one frequency band of light, so as to impart to the absorber sufficient energy to cause at least a portion of said absorber to explode with the resulting explosion forcing at least a portion of said drug into said skin transdermally. 2. A process as in claim 1 wherein said absorber comprises a plurality of carbon particles. 3. A process as in claim 2 wherein said carbon particles are graphite particles having dimensions of about 1 micron. 4. A process as in claim 2 wherein said carbon particles have a dimension of about of about 1 micron. 5. A process as in claim 2 wherein said pulses are pulses from a Nd:YAG laser. 6. A process as in claim 5 wherein said at least one frequency band of light has a wavelength of about 1.06 microns. 7. A process as in claim 5 wherein said pulses define a pulse duration and the pulse duration is about 12 nanoseconds. 8. A process as in claim 5 wherein the energy of the pulses is about 3 Joules/cm.sub.2. 9. A process as in claim 2 wherein said pulses are pulses from a CO.sub.2 laser. 10. A process as in claim 5 or 8 wherein the beam of the laser has a cross section of about 0.5 cm.sub.2. 11. A process as in claim 1 wherein a confinement means, transparent to said at least one frequency band of light is placed firmly over said topically applied drug and absorber for the duration of said forcing explosion for the purpose of confining said forcing explosion. 12. A process as in claim 1, and further comprising the additional step of forcing said drug and absorber into spaces in said skin section prior to illumination. 13. A process as in claim 11 wherein said spaces comprise hair ducts. 14. A process as in claim 12 wherein said spaces in said skin comprises spaces between superficial epidermal skin cells. 15. A process as in claim 12 wherein said spaces in said skin comprises spaces within sebaceous glands. 16. A process as in claim 12 wherein said spaces in said skin comprise spaces adjacent to sebaceous glands. 17. A process as in claim 1 wherein the drag and the absorber are in combination and the weight ratio of the absorber to the drug is about 1:4. 18. A process as in claim 17 wherein the combination is a mixture. 19. A process as in claim 17 wherein the drug coats the absorber. 20. A process as in claim 1 wherein the drug is selected from the group consisting of an antibiotic, an antibacterial, a hormone, a vasodilator, a chemotherapeutic, an anesthetic, an immunomodulator, a PDT sensitizer, an anticoagulant, a nitrite, an enzyme, a radio isotope, and a deposition form. 21. The process as in claim 20 wherein the antibiotic is selected from the group consisting of Bacitracin, Neomycin and PolysinB, and mixtures thereof. 22. The process as in claim 20 wherein the antibacterial is mycostatin. 23. The process as in claim 20 wherein the hormone is hydrocortisone. 24. The process as in claim 20 wherein the vasodilator is minoxidil. 25. The process as in claim 20 wherein the chemotherapeutic is adriamycin. 26. The process as in claim 20 wherein the anesthetic is lidocaine. 27. The process as in claim 20 wherein the immunomodulator is intron A. 28. The process as in claim 20 wherein the PDT sensitizer is selected from the group consisting of ALA, HPD and photophrin, and mixtures thereof. 29. The process as in claim 20 wherein the anticoagulant is heparin. 30. The process as in claim 20 wherein the nitrite is nitroglycerin. 31. The process as in claim 20 wherein the enzyme is streptase. 32. The process as in claim 20 wherein the deposition form is selected from the group consisting of a liposome, a magnetic fluid drug, and a coacervate. 33. The process as in claim 20 wherein the radio isotope is selected from the group consisting of Be and Cd, and mixtures thereof.

Details for Patent 5,713,845

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2011-10-29
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2011-10-29
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2011-10-29